Skip to main content
. 2018 Dec 13;12:79–92. doi: 10.1016/j.omto.2018.12.003

Figure 1.

Figure 1

CRAd-S-pk7 NSCs for Ovarian Cancer

(A) GEO Accession Viewer data showing survivin (BIRC5 gene ID: 202095_s_at) expression in cisplatin-resistant patient tumors (185 samples) and 10 healthy tissues (10 samples). (B) Analysis of GTExPortal data available via Protein Atlas showing survivin expression in various peritoneal tissues. Expression values are shown in RPKM (reads per kilobase of transcript per million mapped reads), calculated from a gene model in which isoforms were collapsed to a single gene. No other normalization steps were applied. Boxplots show median and 25th and 75th percentiles; points are displayed as outliers if they are greater than or less than 1.5 times the interquartile range. (C) Cbioportal Oncoprint compact visualization of mRNA expression scores of three putative CRAd-S-pk7 entry receptors in the 100 patient samples included in The Cancer Genome Atlas serous ovarian cancer project that had survivin amplification (311 patients total). Red indicates amplification; blue indicates deep deletion. BIRC5, survivin; heparin sulfate proteoglycans: GPC1, glypican 1; HSPG2, perlecan; SDC1, Syndecan 1.